about
A Compendium for Mycoplasma pneumoniaeChronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches.Airways disease: phenotyping heterogeneity using measures of airway inflammation.Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Mycoplasmas and ureaplasmas as neonatal pathogens.Mycoplasma pneumoniae and its role in asthmaClarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model studyAzithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot studyMacrolide antibiotics and survival in patients with acute lung injury.Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expressionMacrolides in cystic fibrosis.Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?Azithromycin reduces inflammation in a rat model of acute conjunctivitis.Azithromycin treatment increases survival of high-risk corneal allotransplants.Telithromycin in lower respiratory tract infections.Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management.Cellular and molecular biology of airway mucins.Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis.Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.Inflammatory properties of antibiotic-treated bacteria.The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis.Azithromycin paradox in the treatment of cystic fibrosis airway disease.Suppression of oxidant-induced glutathione synthesis by erythromycin in human bronchial epithelial cells.Resolution of chronic ocular sarcoidosis with antimycobacterial therapy.In Vitro Anti-inflammatory and Immunomodulatory Effects of Ciprofloxacin or Azithromycin in Staphylococcus aureus-Stimulated Murine Macrophages are Beneficial in the Presence of Cytochalasin D.Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression.Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.24/7 intensivist coverage, macrolides in acute lung injury, and roflumilast.Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.Azithromycin inhibits IL-5 production of T helper type 2 cells from asthmatic children.Reduction of RBL–2H3 cells degranulation by nitroaromatic compounds from a Bacillus strain associated to the Amazonian sponge Metania reticulata
P2860
Q26752589-C5E05CEF-FA12-463E-98C8-8AD25A59CE85Q30473876-118CA134-8CE3-488A-AA87-614309C1AB3CQ33864952-95769717-4984-4C69-B0BE-085D744C6288Q33983140-1D03C84C-DA8D-4602-9BE6-9C33EBBC6E34Q34097662-55A94E10-FC95-43F3-9309-08B870BA54A2Q34653507-39F75CCB-1594-47C8-A676-C03B66B1B265Q35654815-03CC505D-D7A5-4CB9-B8A6-3C31544DCC9EQ35850824-BCE8BB75-58B3-42E9-96EE-9F0086151470Q35929943-E11B3D6E-3FB2-48A1-A249-019943193592Q36290459-82C087DE-71D4-43D7-9101-1E761C9C339CQ36309930-080F01D5-7F08-4C5A-96F3-79BB6999A99EQ36376519-B95BABF1-6652-4799-A175-4F7F607ACC89Q36574136-3592B205-1B95-43B0-BE98-3D3E798684CFQ36755971-0F736B5A-5F6E-4699-BF77-74C0C150CE26Q36895727-A379E3AE-FFA7-4BF4-8B2B-8F47424A42FDQ38078833-193D8738-FD63-4273-9F80-7EBD02CB94DFQ38085109-E484E86C-BFEC-484A-87E1-DCBC992F7F05Q38178836-E73CF58E-00F6-4468-B801-ADB8FA7E71F1Q38498597-C29D2C30-4072-4669-9DF9-B58F8D3C17CCQ38925706-BD58B4FE-3EEE-48A6-9A5F-26D9DB50E5C3Q38941353-E545F120-5939-4AA4-9E76-137A5204E682Q39254062-0535FF6D-3F1E-4EC8-AA05-B2D819EB2246Q39496476-9A89C34E-20EE-4233-A999-7B703A3263A7Q39835134-38E79488-620D-4659-B34E-CC0239864A4EQ40046116-036D3164-6CC1-4547-B6DB-160EDEBF9067Q41549842-156DB960-0DC7-41A7-B4A9-38D35AE160E0Q41645682-AB69B68B-95E1-4C0D-ADF7-2CC1BAAFAE2BQ43261580-6D902AF6-9028-4BB7-93E3-3E49E4FF8D48Q44966446-C9BA5438-F576-4543-8F73-F9F339D62144Q46979941-299ADAEC-F087-4B46-8A3C-0FD17098D51BQ51724876-EBF39825-AA07-4E30-96CD-885C1CE89BAAQ53246710-FD748CC5-8409-4C9B-A815-8699592EA7F7Q57023133-2F840475-6CD1-4A96-8F82-D0DE138D930D
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The effects of macrolides on inflammatory cells.
@ast
The effects of macrolides on inflammatory cells.
@en
type
label
The effects of macrolides on inflammatory cells.
@ast
The effects of macrolides on inflammatory cells.
@en
prefLabel
The effects of macrolides on inflammatory cells.
@ast
The effects of macrolides on inflammatory cells.
@en
P1433
P1476
The effects of macrolides on inflammatory cells.
@en
P2093
Jun Tamaoki
P304
41S-50S; quiz 51S
P356
10.1378/CHEST.125.2_SUPPL.41S
P407
P433
P577
2004-02-01T00:00:00Z